Jula Inrig @InrigJula

Today we announced that we plan to submit a supplemental New Drug Application (sNDA) to the U.S. FDA for sparsentan in focal segmental glomerulosclerosis (#FSGS). Press release: bit.ly/4gDGTGq #InRareForLife

0 2 9 759 1

View Details

Travere Therapeutics @TravereRare

2 years ago

We’d like to extend a huge thank you to @ASNKidney and to everyone who joined us at #ASN24 #KidneyWk. It was a pleasure coming together and sharing our clinical data and research in #IgAN and #FSGS. Thank you to all those who contributed to another thought-provoking and inspiring meeting on advances in #RareKidneyDisease (RKD).

0 1 14 685 0

View Details

Jula Inrig @InrigJula

2 years ago

@DanTheKidneyMan @KidneyMed @ASNKidney360 @MikeAllonK360 @MRrenaldoc Some great people shown here!

0 0 1 61 0

View Details

Travere Therapeutics @TravereRare

2 years ago

“When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced,” writes Jula Inrig, M.D., chief medical officer at Travere. Check out her recent article about #RareKidneyDisease and #IgAnephropathy in Fierce Biotech. #InRareForLife bit.ly/3BGDsA3

0 1 2 240 0

View Details

Travere Therapeutics @TravereRare

2 years ago

Today we announced that we’ll present 11 abstracts at the upcoming @ASNKidney #ASN24 #KidneyWk in San Diego, CA, later this month on our work in #RareKidneyDisease. #InRareForLife bit.ly/4eUMh7A

0 2 6 585 0

View Details

Jula Inrig @InrigJula

2 years ago

@OhioStateNeph @OSUWexMed @BradRovin Congratulations, well deserved!

0 0 2 39 0

View Details

CheckRare @CheckRare

2 years ago

Jula Inrig, MD, Chief Medical Officer at Travere Therapeutics, discusses a clinical trial that tested sparsentan for treatment of IgA nephropathy, compared to traditional RAS inhibitors. #CheckRare #RareDisease #IgANephropathy checkrare.com/clinical-trial…

0 1 2 174 0

View Details

Hans-Joachim Anders @hjanders_hans

2 years ago

JCI Insight - Sparsentan improves glomerular hemodynamics, cell functions and tissue repair in a mouse model of FSGS insight.jci.org/articles/view/…

1 5 26 2K 5

View Details

Jula Inrig @InrigJula

2 years ago

For all the years I’ve treated people living with IgAN, today marks a new chapter and brings me profound hope for this patient community that has waited for so long. #InRareForLife

Travere Therapeutics @TravereRare

2 years ago

We are excited to announce that our medicine for the treatment of #IgAnephropathy was granted full approval by the FDA. Today’s approval marks an important milestone in transforming treatment for people living with #RareKidneyDisease. Press release: bit.ly/4eakAr1

0 7 26 8K 4

0 3 18 2K 1

View Details

Travere Therapeutics @TravereRare

2 years ago

0 7 26 8K 4

View Details

Jula Inrig @InrigJula

2 years ago

@julierenal Life is so much better with a lot of laughter…and champagne! Let’s keep the tradition going for decades to come :)

0 0 1 40 0

View Details

Travere Therapeutics @TravereRare

2 years ago

“There’s always a little love for the glomerulus,” said Jula Inrig, M.D., CMO of Travere Therapeutics during a podcast with the @ISGDtweets. Jula talks about her career, Kidney Health Initiative, endothelin physiology, and clinical trials of sparsentan in IgAN and FSGS

0 3 10 617 0

View Details

HCPLive @HCPLiveNews

2 years ago

Findings demonstrated a slower decline in kidney function for patients treated with sparsentan or irbesartan compared with standard of care in both real-world and clinical trial settings. hcplive.com/view/irbesarta… #NKFClinicals #SCM24 #LateBreakers

0 5 6 631 0

View Details

American Physiological Society @APSPhysiology

2 years ago

#APSselect mouse study from @AJPRenal finds the nephropathy drug sparsentan improves changes in the kidney associated with inflammatory genes and pathways: ow.ly/gsgI50RtUt8 CC: @AJPRenalEIC

0 7 6 883 0

View Details

Travere Therapeutics @TravereRare

2 years ago

We are delighted to share abstracts at @nkf #SCM24 on our research in #RKD, including analyses comparing the effect of sparsentan as seen in the Phase 3 PROTECT Study in slowing kidney function decline versus RASi in real-world use and in clinical trials in patients with #IgAN.

0 3 8 573 0

View Details

World Congress of Nephrology @ISNWCN

2 years ago

"SPARSENTAN as First-line Treatment of Incident Patients With IgAN: Preliminary Findings from the SPARTAN Trial" by @toomuchaltitude, et al, was presented at WCN'24. Their work was transformed into a visual abstract by #ISNWCN Social Media Team member @Ironken6

1 12 20 991 1

View Details

International Society of Glomerular Disease @ISGDtweets

2 years ago

In our latest GN in Ten episode, @koyaljainMD and @kdjhaveri chat with @InrigJula about endothelin, sparsentan, the art & science of clinical trial design, clinical research careers outside academia, and how we got to this "golden era" of neph trials. eu1.hubs.ly/H08RsYt0